Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapcabtagene Autoleucel in Adult Patients With B-Cell Malignancies
NCT03960840Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2019
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 8
01
Overview
A Phase 2 trial of rapcabtagene autoleucel in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), sponsored by Novartis. Started Jun 2019; status: active, not recruiting.
02
Drugs
rapcabtagene autoleucel
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)diffuse large B-cell lymphoma (DLBCL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03960840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03960840.